ST. LOUIS, Feb. 12, 2015 /PRNewswire/ --
HIGHLIGHTS:
Q4 2014 Results (all percentage changes are against the same period in 2013)
- Reported sales increased 3% to $705 million. Organic sales growth was 7% with changes in foreign currency exchange rates reducing sales by 5%. Net impact from recent acquisitions and divestitures increased sales by 1%.
- By business unit, organic sales growth was 4% in Research, 8% in Applied and 14% in SAFC Commercial.
- Reported diluted EPS was $1.11 compared to $1.08 in Q4 2013. Excluding costs related to restructuring, mergers and acquisitions and certain 2013 tax benefits, adjusted diluted EPS was $1.14 compared to $1.02 in Q4 2013, an increase of 12%. Changes in foreign currency exchange rates compared to the same period last year reduced adjusted EPS by $0.04.
- On February 10, 2015 the Company’s Board of Directors approved a quarterly cash dividend of $0.23 per share to be paid on March 13, 2015, to shareholders of record on February 27, 2015.
Full-Year 2014 Results (all percentage changes are against the full-year 2013)
- Reported sales increased 3% to $2.79 billion. Organic sales growth was 4% with changes in foreign currency exchange rates reducing sales by 1%.
- By business unit, organic sales growth was 1% in Research, 8% in Applied and 6% in SAFC Commercial.
- Reported diluted EPS was $4.17 compared to $4.06 in 2013. Excluding costs related to restructuring, mergers and acquisitions and certain 2013 tax benefits, adjusted diluted EPS was a record-high $4.37 compared to $4.12 in 2013, an increase of 6%. Changes in foreign currency exchange rates compared to last year reduced adjusted EPS by $0.09. Excluding this impact, 2014 adjusted diluted EPS would have increased by 8%.
CEO’s STATEMENT:
Commenting on 2014 performance, President and CEO Rakesh Sachdev said, “I am proud of all of our employees. In what has become a very eventful and pivotal year in the history of our Company, their hard work and dedication to our customers resulted in another record-breaking year of sales and earnings. I am especially pleased to report that annual adjusted EPS increased for the 40th consecutive year.
“Our three business units, Research, Applied and SAFC, continue to provide market-leading products and services and each business has elevated its customer-centric strategies by responding to the needs of their global, diverse customer bases. This resulted in solid organic sales growth for the year with the fourth quarter of 2014 at 7%, the highest quarterly performance in almost four years.
“In the Research business unit, we had a good finish to 2014 with growth contribution from all segments and geographies. Research customers appreciate the high quality and availability of our wide range of products as well as the ease of ordering through our industry-leading e-Commerce platform. In the fourth quarter, we saw improved U.S. academic spending and had another double-digit sales growth performance in China as well as a return to double-digit growth in India.
“In the Applied business unit, we had steady performance throughout 2014 with contributions from all segments and all geographies. In the fourth quarter of 2014, the Diagnostics & Testing segment grew double digits, again led by demand for our analytical standards. Our focus on providing high quality, innovative products to customers in regulated diagnostics and testing markets continues to open opportunities with new customers and generate double-digit growth with our strategic accounts.
“In the SAFC business unit, we had a strong finish to the year with 14% organic sales growth in the fourth quarter led by double-digit growth of our Life Science Products. Biopharma and Pharma products contributed to growth in this segment, led by new zinc-finger nuclease licensing agreements and PharmaGrade product sales. The Life Science Services segment had another solid quarter of growth, led by demand in service sales for gene therapy projects. We are now reaping the benefits of our successful integration of BioReliance into SAFC. The top-line synergies this integration has created has led to six consecutive double-digit sales growth quarters for Life Science Services.
“The Global Supply Chain initiatives we rolled out at the beginning of the year have had a meaningful impact on our results. These initiatives, coupled with the ongoing cost reduction activities throughout the entire organization, helped drive a 70 basis point improvement in full-year 2014 gross margin despite a 20 basis point negative impact from changes in foreign currency exchange rates.
“In January at the World Economic Forum in Davos, we were named by Corporate Knights as the 38th Most Sustainable Corporation in the World. This is the second consecutive year for Sigma-Aldrich to be named to this prestigious list, and we are proud to be one of only 20 U.S. companies to receive this distinction in the 2015 Global 100 list. This is a testament to our sustainability efforts in the communities where we live and work.”
Mr. Sachdev continued, “Looking to the future, we are excited about the opportunity to join forces with Merck KGaA of Darmstadt, Germany. We continue to expect the transaction to close mid-2015, subject to receipt of certain antitrust and government approvals and other customary closing conditions. We believe that our eighty-year mission of enabling science to improve the quality of life by providing one of the broadest portfolios of high quality products in the industry will significantly benefit the combination of the two companies, our employees and, most importantly, our large world-wide customer base.”
Q4 2014 AND FULL-YEAR 2014 RESULTS:
Reported sales for the fourth quarter of 2014 were $705 million, a 3% increase from the same quarter in 2013. Organic sales growth in the quarter was 7%. Acquisitions and divestitures increased sales by 1% in the quarter, and changes in foreign currency exchange rates reduced sales by 5%.
For the full-year 2014, reported sales were $2.79 billion, a 3% increase from full-year 2013. Organic sales growth was 4%, and changes in foreign currency exchange rates reduced sales by 1%.
In the fourth quarter of 2014, reported sales of the Research business unit ($341 million in sales, 48% of overall sales) declined by 2% compared to the same period last year. Organic sales growth was 4%. Changes in foreign currency exchange rates reduced sales by 6%. All segments (Academic, Pharma and Dealers) and geographies contributed to organic sales growth during the quarter.
For the full-year 2014, reported sales of the Research business unit ($1.40 billion in sales, 51% of overall sales) were flat compared to 2013. Organic sales growth was 1%, and changes in foreign currency exchange rates reduced sales by 1%.
Reported fourth quarter 2014 sales of the Applied business unit ($167 million in sales, 24% of overall sales) increased by 7% compared to the same period last year. Organic sales growth was 8%. Acquisitions added 3% to sales in the quarter, and changes in foreign currency exchange rates reduced sales by 4%. Applied sales growth was driven by double-digit growth in the Diagnostics & Testing segment.
For the full-year 2014, reported sales of the Applied business unit ($680 million, 24% of overall sales) increased 8% compared to 2013. Organic sales growth was 8%. Acquisitions increased sales by 1%, and changes in foreign currency exchange rates reduced sales by 1%.
Reported fourth quarter 2014 sales of the SAFC Commercial business unit ($197 million in sales, 28% of overall sales) grew by 9% compared to the same period last year. Organic sales growth was 14%. Divestitures reduced reported sales by 1%, and changes in foreign currency exchange rates reduced sales by 4%. Growth was led by double-digit organic sales growth in both the Life Science Products and Life Science Services segments.
For full-year 2014, reported sales of the SAFC Commercial business unit ($701 million, 25% of overall sales) increased by 4%. Organic sales growth was 6%. Impact from divestitures decreased sales by 1%, and changes in foreign currency exchange rates decreased sales by 1%.
Excluding restructuring and mergers and acquisitions costs, adjusted operating income in the fourth quarter of 2014 grew by $5 million, which was an increase of 3% over the same period last year. Changes in foreign currency exchange rates, net of hedging, lowered operating income when compared to the same period last year by $6 million.
For full-year 2014, adjusted operating income grew by $32 million, an increase of 5% from 2013. The adjusted operating income margin was 25.7%, an improvement of 40 basis points from 2013. Changes in foreign currency exchange rates reduced otherwise reported adjusted operating income margin by 40 basis points. Excluding the impact of changes of in foreign currency exchange rates, 2014 adjusted operating income would have increased by $47 million from 2013, an increase of 7%.
The adjusted effective tax rate (excluding restructuring and mergers and acquisitions costs) for the fourth quarter of 2014 was 22% as compared to 28% in the same period last year. The lower tax rate is primarily due to an increased benefit from favorable tax rates in foreign jurisdictions, the reinstatement of the U.S. R&D tax credit for 2014 in December, and the finalization of prior year tax filings.
The adjusted effective tax rate for full-year 2014 was 26% as compared to 27% in 2013. The lower tax rate in 2014 is primarily due to an increased benefit from favorable tax rates in foreign jurisdictions.
OTHER INFORMATION:
Cash Flow and Debt: For full-year 2014, net cash provided by operating activities was $640 million compared to $641 million in 2013. Capital expenditures were $118 million as compared to $100 million in 2013. Free cash flow was $522 million as compared to $541 million in 2013. The Company’s debt to capital ratio was 12% at December 31, 2014, compared to 11% at December 31, 2013.
Share Repurchases: The Company did not repurchase shares in the fourth quarter of 2014. During the first three quarters of 2014, the Company repurchased approximately 900,000 shares for approximately $85 million. There were approximately 119 million shares outstanding at December 31, 2014.
Conference Call Information: In light of the announced transaction with Merck KGaA, the Company will no longer hold conference calls for quarterly and annual earnings. The transaction with Merck KGaA, which is expected to close in mid-2015, is subject to customary closing conditions, including regulatory approvals.
Cautionary Statement: This release contains forward-looking statements. Such statements involve risk and uncertainty, including financial and business environment risks and projections. Such statements include those preceded or followed by, or including the words, “continue,” “expect,” “believe,” “will be,” “will continue,” “enabling,” or similar expressions, and other statements contained herein regarding matters that are not historical facts. Additionally, this release contains forward-looking statements relating to certain acquisitions and transactions, future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including, without limitation, statements with respect to the Company’s expectations, goals, beliefs, intentions and the like regarding future sales, earnings, return on equity, return on invested capital, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions and other matters. These statements are based on assumptions regarding the Company’s operations, investments and acquisitions and conditions in the markets the Company serves. While the Company believes these statements are reasonable, such statements are subject to risks and uncertainties, including, among others, certain economic, political and technological factors. Actual results could differ materially from those stated or implied in this release, due to, but not limited to, such factors as (1) successfully completing our proposed transaction with Merck KGaA, which is dependent upon and/or may be affected by a number of factors, including, without limitation, timely receipt of regulatory approvals required for the transaction and other customary closing conditions, (2) potential disruption to our business occurring during the period between the announcement of the merger agreement with Merck KGaA and the closing of the transaction, (3) global economic conditions and other factors affecting the creditworthiness of our customers around the world, (4) changes in pricing and the competitive environment and the global demand for the Company’s products, (5) changes in foreign currency exchange rates, (6) changes in research funding and the success of research and development activities, (7) failure of planned sales initiatives in our Research, Applied and SAFC Commercial business units and global supply chain efficiency improvements, (8) dependence on uninterrupted manufacturing operations and a global supply chain, (9) changes in the regulatory environment in which the Company operates, (10) changes in worldwide tax rates or tax benefits from domestic and international operations, including the matters described in Note 12 Income Taxes, to the Company’s consolidated financial statements included in Item 8 of Part II of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 (the “10-K”), (11) exposure to litigation, including, without limitation, product liability claims, (12) the ability to maintain adequate quality standards, (13) reliance on third party package delivery services, (14) an unanticipated increase in interest rates, (15) other changes in the business environment in which the Company operates, (16) acquisitions or divestitures of businesses, (17) the amount of restructuring charges, if any, (18) disruption to our information technology systems, and (19) the outcome of the outstanding matters described in Note 14 Contingent Liabilities and Commitments to the Company’s consolidated financial statements included in Item 8 of Part II of the 10-K. A further discussion of the Company’s risk factors can be found in Item 1A of Part I of the 10-K. The Company does not undertake any obligation to update these forward-looking statements.
About Sigma-Aldrich: Sigma-Aldrich, headquartered in St. Louis, Missouri, is a leading Life Science and Technology company whose biochemical and organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich manufactures and distributes 250,000 chemicals, biochemicals and other essential products and 46,000 equipment products to its global customer base with more than one million scientists and technologists in life science companies, university and government institutions, hospitals and a wide range of industrial companies. The Company operates in 37 countries and has more than 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science, Technology and Service. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.
To read full press release, please clichttp://www.wvnstv.com/story/28090532/sigma-aldrich-nasdaq-sial-reports-record-full-year-2014-sales-of-279-billion-and-record-adjusted-diluted-eps-of-437-reports-q4-2014-adjusted-diluted” target="_blank">here.
Help employers find you! Check out all the jobs and post your resume.
